Antibody response after COVID-19 vaccine BNT162b2 on health care workers in Japan

Vaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response in humans after the COVID-19 vaccination. This single-center, prospective study was conducted in Yokohama, Japan. We included health care workers who had rec...

Full description

Saved in:
Bibliographic Details
Published inJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 27; no. 12; pp. 1713 - 1715
Main Authors Yoshimura, Yukihiro, Sasaki, Hiroaki, Miyata, Nobuyuki, Miyazaki, Kazuhito, Tachikawa, Natsuo
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.12.2021
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Vaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response in humans after the COVID-19 vaccination. This single-center, prospective study was conducted in Yokohama, Japan. We included health care workers who had received two doses of COVID-19 vaccination (BNT162b2) 21 days apart. We measured serum immunoglobulin G (IgG) to nucleoprotein and spike protein of SARS-CoV-2 with commercially available kits before and 7, 14, and 35 days after the first dose of vaccination. A total of 104 workers participated in this study. Of these, 7 participants were seropositive with antibodies to spike protein at baseline and 4 of the 7 seropositive participants had COVID-19 history. The mean level of IgG to spike protein (QT) was 45.2, 1219, 2845, and 23489 AU/mL at baseline, on days 7, 14, and 35, respectively, although the values for nucleoprotein (NG) were 0.2, 0.21, 0.22, and 0.19 S/C, respectively. On day 7, QT in seropositive participants at baseline was elevated, whereas it was not elevated in seronegative participants at baseline until day 14. QT was elevated over the cutoff in all the participants at day 35, but NG did not change between baseline and day 35.
AbstractList Vaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response in humans after the COVID-19 vaccination.BACKGROUNDVaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response in humans after the COVID-19 vaccination.This single-center, prospective study was conducted in Yokohama, Japan. We included health care workers who had received two doses of COVID-19 vaccination (BNT162b2) 21 days apart. We measured serum immunoglobulin G (IgG) to nucleoprotein and spike protein of SARS-CoV-2 with commercially available kits before and 7, 14, and 35 days after the first dose of vaccination.METHODSThis single-center, prospective study was conducted in Yokohama, Japan. We included health care workers who had received two doses of COVID-19 vaccination (BNT162b2) 21 days apart. We measured serum immunoglobulin G (IgG) to nucleoprotein and spike protein of SARS-CoV-2 with commercially available kits before and 7, 14, and 35 days after the first dose of vaccination.A total of 104 workers participated in this study. Of these, 7 participants were seropositive with antibodies to spike protein at baseline and 4 of the 7 seropositive participants had COVID-19 history. The mean level of IgG to spike protein (QT) was 45.2, 1219, 2845, and 23489 AU/mL at baseline, on days 7, 14, and 35, respectively, although the values for nucleoprotein (NG) were 0.2, 0.21, 0.22, and 0.19 S/C, respectively. On day 7, QT in seropositive participants at baseline was elevated, whereas it was not elevated in seronegative participants at baseline until day 14.RESULTSA total of 104 workers participated in this study. Of these, 7 participants were seropositive with antibodies to spike protein at baseline and 4 of the 7 seropositive participants had COVID-19 history. The mean level of IgG to spike protein (QT) was 45.2, 1219, 2845, and 23489 AU/mL at baseline, on days 7, 14, and 35, respectively, although the values for nucleoprotein (NG) were 0.2, 0.21, 0.22, and 0.19 S/C, respectively. On day 7, QT in seropositive participants at baseline was elevated, whereas it was not elevated in seronegative participants at baseline until day 14.QT was elevated over the cutoff in all the participants at day 35, but NG did not change between baseline and day 35.CONCLUSIONSQT was elevated over the cutoff in all the participants at day 35, but NG did not change between baseline and day 35.
Vaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response in humans after the COVID-19 vaccination. This single-center, prospective study was conducted in Yokohama, Japan. We included health care workers who had received two doses of COVID-19 vaccination (BNT162b2) 21 days apart. We measured serum immunoglobulin G (IgG) to nucleoprotein and spike protein of SARS-CoV-2 with commercially available kits before and 7, 14, and 35 days after the first dose of vaccination. A total of 104 workers participated in this study. Of these, 7 participants were seropositive with antibodies to spike protein at baseline and 4 of the 7 seropositive participants had COVID-19 history. The mean level of IgG to spike protein (QT) was 45.2, 1219, 2845, and 23489 AU/mL at baseline, on days 7, 14, and 35, respectively, although the values for nucleoprotein (NG) were 0.2, 0.21, 0.22, and 0.19 S/C, respectively. On day 7, QT in seropositive participants at baseline was elevated, whereas it was not elevated in seronegative participants at baseline until day 14. QT was elevated over the cutoff in all the participants at day 35, but NG did not change between baseline and day 35.
Author Tachikawa, Natsuo
Miyazaki, Kazuhito
Sasaki, Hiroaki
Miyata, Nobuyuki
Yoshimura, Yukihiro
Author_xml – sequence: 1
  givenname: Yukihiro
  surname: Yoshimura
  fullname: Yoshimura, Yukihiro
  email: yu10-yoshimura@city.yokohama.jp
– sequence: 2
  givenname: Hiroaki
  surname: Sasaki
  fullname: Sasaki, Hiroaki
– sequence: 3
  givenname: Nobuyuki
  surname: Miyata
  fullname: Miyata, Nobuyuki
– sequence: 4
  givenname: Kazuhito
  orcidid: 0000-0002-0079-2883
  surname: Miyazaki
  fullname: Miyazaki, Kazuhito
– sequence: 5
  givenname: Natsuo
  surname: Tachikawa
  fullname: Tachikawa, Natsuo
BookMark eNqFkUtrFEEQxxuJmId-AU999DKTfsyjR0SIq-ZBMAhRvDU1NTVub2a71-7ZDfvtnWWDYA7JqQqqfv96_I_ZgQ-eGHsrRS6FrE4X-cIB5koomQuTC2FesCNZ6DqrayMOplwXMtNK_jpkxykthJB1acwrdqiLQqrG6CP2_cyPrg3dlkdKq-ATcehHinx28_PycyYbvgFE54l_-nYrK9UqHjyfEwzjnCNE4vch3lFM3Hl-BSvwr9nLHoZEbx7iCfvx9cvt7CK7vjm_nJ1dZ1iKesxAd0VvJCKqrjBQCD3dUWOPCI1C0UEHpdaSQFTYtWSgRoFC6baCthdVqU_Yx73uat0uqUPyY4TBrqJbQtzaAM7-X_Fubn-HjTW6NKJpJoF3DwIx_FlTGu3SJaRhAE9hnawqK10obZSeWtW-FWNIKVL_b4wUdueFXdidF3bnhRXGTl5MkHkEoRthdGG3jhueRj_sUZoeuHEUbUJHHqlzkXC0XXBP4-8f4Tg47xCGO9o-B_8Fq5O5GA
CitedBy_id crossref_primary_10_3390_vaccines11010051
crossref_primary_10_29328_journal_icci_1001020
crossref_primary_10_1007_s15010_022_01779_x
crossref_primary_10_1016_j_ijid_2022_04_057
crossref_primary_10_1080_14760584_2022_2093722
crossref_primary_10_5937_jomb0_33999
Cites_doi 10.1038/s41586-020-2639-4
10.1016/S0140-6736(21)00501-8
10.1056/NEJMc2101667
10.1128/JCM.00388-21
10.1038/s41591-021-01325-6
10.1128/JCM.00941-20
10.1056/NEJMoa2034577
10.1001/jamainternmed.2020.4616
ContentType Journal Article
Copyright 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
Copyright_xml – notice: 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
– notice: Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
– notice: 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
DBID AAYXX
CITATION
7X8
5PM
DOI 10.1016/j.jiac.2021.08.008
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1437-7780
EndPage 1715
ExternalDocumentID PMC8358099
10_1016_j_jiac_2021_08_008
S1341321X21002208
GroupedDBID ---
--M
-Y2
-~C
.1-
.55
.86
.FO
.~1
0R~
0VY
1N0
1P~
1SB
1~.
2.D
28-
29K
2JY
2P1
2VQ
2~H
30V
4.4
408
409
40D
457
4G.
53G
5GY
5QI
5VS
67Z
6NX
7-5
8P~
8TC
8UJ
95.
95~
AAAJQ
AAEDT
AAEDW
AAIAL
AAIKJ
AAKOC
AALRI
AANXM
AAOAW
AAQFI
AARHV
AATTM
AAXKI
AAXUO
AAYWO
AAYZH
ABFSG
ABJNI
ABMAC
ABMNI
ABMZM
ABQSL
ABXDB
ACDAQ
ACGFS
ACIEU
ACOMO
ACRLP
ACSTC
ACVFH
ADBBV
ADCNI
ADEZE
ADHKG
ADIMF
ADKPE
ADQRH
ADRFC
ADVLN
AEBSH
AEFIE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AEZWR
AFBBN
AFEXP
AFHIU
AFLOW
AFPUW
AFRHN
AFTJW
AFWTZ
AFXIZ
AGCQF
AGGDS
AGHFR
AGJBK
AGQPQ
AGUBO
AHBYD
AHKAY
AHSBF
AHWEU
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AIXLP
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMRAJ
ANKPU
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BA0
BBWZM
BGNMA
BKOJK
BLXMC
BNPGV
CAG
CJTIS
COF
CS3
CSCUP
D-I
DL5
EBS
EFJIC
EFKBS
EJD
EMOBN
EN4
F5P
FDB
FEDTE
FIRID
FYGXN
GBLVA
GQ8
GXS
H13
HF~
HG5
HG6
HMJXF
HVGLF
HZ~
I09
IHE
IXC
IXE
IZIGR
IZQ
I~X
KDC
KOM
KOW
KPH
LAS
M41
M4Y
MA-
MO0
N2Q
N9A
NB0
NDZJH
NU0
O9-
O93
O9G
O9I
OAM
OAUVE
OC~
P-8
P-9
P19
P2P
P9S
PC.
PT5
QOK
QOS
R4E
R89
R9I
RNI
ROL
RPX
RRX
RSV
RZK
S1Z
S26
S27
S28
S37
S3B
SDE
SDH
SDM
SMD
SOJ
SPCBC
SSH
SSZ
SV3
T13
T16
T5K
TSK
TSV
TT1
TUC
U2A
VC2
WJK
WK8
X7M
Z45
Z5R
~A9
~EX
~G-
-5E
-5G
-BR
0SF
AACTN
AAIAV
ABLVK
ABTEG
ABYKQ
ADINQ
AFKWA
AFNRJ
AHPSJ
AJBFU
AJOXV
AMFUW
EFLBG
GQ6
NCXOZ
RIG
SSI
SZN
Z7U
Z82
Z87
Z8O
Z8V
Z91
AAYXX
AFCTW
AGRNS
CITATION
7X8
5PM
ID FETCH-LOGICAL-c507t-a3d4f81ccc2d48a4032027cfcca92c0dada5331ea06cdbe8a7c0c023b6abf0653
IEDL.DBID .~1
ISSN 1341-321X
1437-7780
IngestDate Thu Aug 21 18:21:00 EDT 2025
Thu Jul 10 17:51:24 EDT 2025
Thu Apr 24 23:01:51 EDT 2025
Tue Jul 01 02:23:37 EDT 2025
Fri Feb 23 02:43:23 EST 2024
Tue Aug 26 18:43:08 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords COVID-19
Antibody
Vaccination
Health care worker
Japan
Language English
License Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c507t-a3d4f81ccc2d48a4032027cfcca92c0dada5331ea06cdbe8a7c0c023b6abf0653
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-0079-2883
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8358099
PMID 34412983
PQID 2563423823
PQPubID 23479
PageCount 3
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8358099
proquest_miscellaneous_2563423823
crossref_primary_10_1016_j_jiac_2021_08_008
crossref_citationtrail_10_1016_j_jiac_2021_08_008
elsevier_sciencedirect_doi_10_1016_j_jiac_2021_08_008
elsevier_clinicalkey_doi_10_1016_j_jiac_2021_08_008
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-12-01
PublicationDateYYYYMMDD 2021-12-01
PublicationDate_xml – month: 12
  year: 2021
  text: 2021-12-01
  day: 01
PublicationDecade 2020
PublicationTitle Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
PublicationYear 2021
Publisher Elsevier Ltd
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
– name: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd
References Bryan, Pepper, Wener, Fink, Morishima, Chaudhary (bib4) 2020; 58
Narasimhan, Mahimainathan, Araj, Clark, Markantonis, Green (bib5) 2021
Wu, Liu, Wang, Lu, Wang, Gu (bib9) 2020; 180
World Health Organization (bib2)
Krammer, Srivastava, Alshammary, Amoako, Awawda, Beach (bib11) 2021; 384
World Health Organization (bib1)
Manisty, Otter, Treibel, McKnight, Altmann, Brooks (bib7) 2021; 397
Polack, Thomas, Kitchin, Absalon, Gurtman, Lockhart (bib6) 2020; 383
bib10
Mulligan, Lyke, Kitchin, Absalon, Gurtman, Lockhart (bib3) 2020; 586
Ebinger, Fert-Bober, Printsev, Wu, Sun, Prostko (bib8) 2021
Polack (10.1016/j.jiac.2021.08.008_bib6) 2020; 383
Ebinger (10.1016/j.jiac.2021.08.008_bib8) 2021
Manisty (10.1016/j.jiac.2021.08.008_bib7) 2021; 397
Wu (10.1016/j.jiac.2021.08.008_bib9) 2020; 180
Krammer (10.1016/j.jiac.2021.08.008_bib11) 2021; 384
World Health Organization (10.1016/j.jiac.2021.08.008_bib2)
World Health Organization (10.1016/j.jiac.2021.08.008_bib1)
Mulligan (10.1016/j.jiac.2021.08.008_bib3) 2020; 586
Bryan (10.1016/j.jiac.2021.08.008_bib4) 2020; 58
Narasimhan (10.1016/j.jiac.2021.08.008_bib5) 2021
References_xml – year: 2021
  ident: bib5
  article-title: Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays among infected, recovered, and vaccinated groups
  publication-title: J Clin Microbiol
– ident: bib1
  article-title: WHO coronavirus (COVID-19) dashboard
– volume: 58
  start-page: 20
  year: 2020
  ident: bib4
  article-title: Performance characteristics of the abbott architect SARS-CoV-2 IgG assay and seroprevalence in boise, Idaho
  publication-title: J Clin Microbiol
– volume: 383
  start-page: 2603
  year: 2020
  end-page: 2615
  ident: bib6
  article-title: Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine
  publication-title: N Engl J Med
– volume: 180
  start-page: 1356
  year: 2020
  end-page: 1362
  ident: bib9
  article-title: Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in shanghai, China
  publication-title: JAMA Intern Med
– ident: bib10
– volume: 384
  start-page: 1372
  year: 2021
  end-page: 1374
  ident: bib11
  article-title: Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine
  publication-title: N Engl J Med
– year: 2021
  ident: bib8
  article-title: Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
  publication-title: Nat Med
– volume: 586
  start-page: 589
  year: 2020
  end-page: 593
  ident: bib3
  article-title: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
  publication-title: Nature
– volume: 397
  start-page: 1057
  year: 2021
  end-page: 1058
  ident: bib7
  article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
  publication-title: Lancet
– ident: bib2
  article-title: COVID-19 vaccines
– ident: 10.1016/j.jiac.2021.08.008_bib1
– volume: 586
  start-page: 589
  year: 2020
  ident: 10.1016/j.jiac.2021.08.008_bib3
  article-title: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
  publication-title: Nature
  doi: 10.1038/s41586-020-2639-4
– volume: 397
  start-page: 1057
  year: 2021
  ident: 10.1016/j.jiac.2021.08.008_bib7
  article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00501-8
– volume: 384
  start-page: 1372
  year: 2021
  ident: 10.1016/j.jiac.2021.08.008_bib11
  article-title: Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2101667
– year: 2021
  ident: 10.1016/j.jiac.2021.08.008_bib5
  article-title: Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays among infected, recovered, and vaccinated groups
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.00388-21
– year: 2021
  ident: 10.1016/j.jiac.2021.08.008_bib8
  article-title: Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01325-6
– ident: 10.1016/j.jiac.2021.08.008_bib2
– volume: 58
  start-page: 20
  year: 2020
  ident: 10.1016/j.jiac.2021.08.008_bib4
  article-title: Performance characteristics of the abbott architect SARS-CoV-2 IgG assay and seroprevalence in boise, Idaho
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.00941-20
– volume: 383
  start-page: 2603
  year: 2020
  ident: 10.1016/j.jiac.2021.08.008_bib6
  article-title: Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2034577
– volume: 180
  start-page: 1356
  year: 2020
  ident: 10.1016/j.jiac.2021.08.008_bib9
  article-title: Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in shanghai, China
  publication-title: JAMA Intern Med
  doi: 10.1001/jamainternmed.2020.4616
SSID ssj0017588
Score 2.31507
Snippet Vaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response in humans after...
SourceID pubmedcentral
proquest
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 1713
SubjectTerms Antibody
COVID-19
Health care worker
Japan
Original
Vaccination
Title Antibody response after COVID-19 vaccine BNT162b2 on health care workers in Japan
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1341321X21002208
https://dx.doi.org/10.1016/j.jiac.2021.08.008
https://www.proquest.com/docview/2563423823
https://pubmed.ncbi.nlm.nih.gov/PMC8358099
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS-QwEA_ivfgi6il-E-HwRes2abZNH_f2lFVxVVxl30K-ihXJiq7Cvvi3X6ZpVxcOD3xsm4EkM5kZmt_8BqFfGTVFoayNDCFFxHzKHCnL4G8TSdrGJBmVUO980U97t-xs2B7OoW5TCwOwytr3B59eeev6TavezdZTWbZugIosoWRIgUWUVgW_jGVg5UfvU5iHj45V70kYHMHounAmYLweSgk0hjTQeEKLyX8Hp0_J5yx08lMsOllCi3USiTthnstozroVtH8VWKgnh3jwUVT1coj38dUHP_XkJ7ruuHGpRmaCnwNA1uKqUzjuXt6d_olIjt-khvt2_Ls_IClVFI8cDgWTGJBiGMBcPm3EpcNnPti6VXR7cjzo9qK6s0Kkff43jmRiWMGJ1poaxiWruqhnuvDqzKmOjTTSp4HEyjjVRlkuMx1rH91VKlUBbLZraN6NnF1HuOA2lzFRwNPGuLF5apOY6ZhnkqaWJBuINFsqdE07Dt0vHkWDL3sQoAYBahDQEjPmG-hgKvMUSDe-HJ00mhJNOal3gMLHhC-l2lOpGYP7r9xeYwzCn0S4XpHOjl5fhE8egU6RU7_mbMZKposALu_ZL668rzi9OVxH5_nmN2e1hRbgKeBsttH8-PnV7vhsaax2q-Owi350Ts97_b8JDBUE
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOcAF8RTlaSTohYaNHW_iHHooLdVuH0sRW7Q316-IVChbdbet9tI_xR9kJk62XQkVCanXJBPZM_bMJP7mG0LeZ9wVhfE-cowVkYCUOTJe4N8mlnSdSzKusd55f5D2DsXOqDtaIr_bWhiEVTa-P_j02ls3VzqNNjsnZdn5jlRkCWcjjiyiPJYNsnLXzy7gu22y3t8CI3_gfPvLcLMXNa0FIgsJ0DTSiROFZNZa7oTUom4jntkC5pNzGzvtNORBzOs4tc54qTMbWwhvJtWmQDpXeO8dcleAu8C2CZ8u57gSCMd1s0scXYTDayp1AqjsuNTIm8gDbyj2tPx7NLyW7S5iNa8Fv-2H5EGTtdKNoJhHZMlXj8nqQaC9nq3R4VUV12SNrtKDK0Ls2RPybaOalmbsZvQ0IHI9rVuT082vP_pbEcvpubZ4wE8_D4Ys5YbTcUVDhSZFaBpF9BjkqbSs6A5E9-opObwVfT8jy9W48s8JLaTPdcwMEsMJ6Xye-iQWNpaZ5qlnyQphrUqVbXjOsd3GL9UC2o4VmkGhGRT24IzlCvk4lzkJLB83Pp20llJt_Sp4XAVB6Eap7lxqYYX_U-5duxgUbH08z9GVH59NFGSryN8oOcw5W1gl80kgefjinar8WZOISzz_zvMX_zmqt-Reb7i_p_b6g92X5D7eCSCfV2R5enrmX0OqNjVv6q1BydFt78U_9Q1SnA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antibody+response+after+COVID-19+vaccine+BNT162b2+on+health+care+workers+in+Japan&rft.jtitle=Journal+of+infection+and+chemotherapy+%3A+official+journal+of+the+Japan+Society+of+Chemotherapy&rft.au=Yoshimura%2C+Yukihiro&rft.au=Sasaki%2C+Hiroaki&rft.au=Miyata%2C+Nobuyuki&rft.au=Miyazaki%2C+Kazuhito&rft.date=2021-12-01&rft.pub=Elsevier+Ltd&rft.issn=1341-321X&rft.volume=27&rft.issue=12&rft.spage=1713&rft.epage=1715&rft_id=info:doi/10.1016%2Fj.jiac.2021.08.008&rft.externalDocID=S1341321X21002208
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1341-321X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1341-321X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1341-321X&client=summon